Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Abstract: The omnidirectional ultra-wideband antenna is a variant on a monocone antenna, particularly including a supplemental radiating element. The omnidirectional ultra-wideband antenna includes an electrically conductive conical surface having a vertex end and a base end, and a supplemental radiating element having a first portion and a second portion. The first portion extends from the base end of the electrically conductive conical surface, the first portion being positioned between the base end of the electrically conductive conical surface and the second portion. The vertex end of the electrically conductive conical surface is positioned adjacent to, and spaced apart from, a first surface of a ground plane plate. At least one electrically conductive rod is provided, a first end of the rod being secured to the second portion, and a second end of each rod being mounted on the first surface of the ground plane plate.

Abstract: The omnidirectional multiband antenna is a variant on a monocone antenna, particularly including a corrugated extending surface for lowering the low frequency cutoff of the monocone antenna. The omnidirectional multiband antenna includes an electrically conductive conical surface, having a vertex end and a base end, and at least one electrically conductive annular member mounted on the base end. The at least one electrically conductive annular member is formed from a plurality of stacked segments and has a corrugated exterior surface. The vertex end of the electrically conductive conical surface is positioned adjacent to, and spaced apart from, a first surface of a ground plane plate. A plurality of cylindrical rods is provided, a first end of each rod being secured to the at least one electrically conductive annular member, and a second end of each rod being mounted on the first surface of the ground plane plate.

Abstract: The ultra-wideband unipole antenna is a variant on a monocone antenna, including a plurality of electrically conductive rods that act as a parallel inductive-capacitive (L-C) network for improving the impedance match between the radiating element of the antenna and the antenna's feed. An electrically conductive conical surface having a vertex end and a base end acts as the radiating element. The vertex end is positioned adjacent to, and spaced apart from, a ground plane plate. Each electrically conductive rod has opposed first and second ends, the first end being secured to the electrically conductive conical surface, and the second end being secured to the ground plane plate. A coaxial cable feed line has a center conductor and an outer conductor. The center conductor is in electrical communication with the vertex end of the electrically conductive conical surface, and the outer conductor is in electrical communication with the ground plane plate.

Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Abstract: The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.

Abstract: Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.

Abstract: The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.

Abstract: The present invention relates to a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method of monitoring development or progression of pulmonary fibrosis in a human subject, a method of monitoring or predicting exacerbation of symptoms in a human subject with pulmonary fibrosis as well as a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms.